Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Preparation of cell cultures and vaccinia virus stocks.

Literature DB >> 18429178

Preparation of cell cultures and vaccinia virus stocks.

P L Earl¹, N Cooper, L S Wyatt, B Moss, M W Carroll.

Abstract

This unit describes the maintenance of cell lines used with vaccinia virus, both in monolayer cultures and in suspension. The suspended cell culture is then used in the preparation of vaccinia virus stocks. The preparation of chick embryo fibroblasts (CEF) is also presented for use in the production of the highly attenuated and host range-restricted modified vaccinia virus Ankara (MVA) strain of vaccinia virus. Additionally, support protocols are presented for the titration of standard and MVA vaccinia virus stocks.

Entities: Disease Species

Mesh：

Year: 2001 PMID： 18429178 PMCID： PMC5575744 DOI： 10.1002/0471140864.ps0512s13

Source DB: PubMed Journal: Curr Protoc Protein Sci ISSN： 1934-3655

4 in total

1. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence.

Authors: H Meyer; G Sutter; A Mayr
Journal: J Gen Virol Date: 1991-05 Impact factor: 3.891

Review 2. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses.

Authors: G Antoine; F Scheiflinger; F Dorner; F G Falkner
Journal: Virology Date: 1998-05-10 Impact factor: 3.616

3. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line.

Authors: M W Carroll; B Moss
Journal: Virology Date: 1997-11-24 Impact factor: 3.616

4. Nonreplicating vaccinia vector efficiently expresses recombinant genes.

Authors: G Sutter; B Moss
Journal: Proc Natl Acad Sci U S A Date: 1992-11-15 Impact factor: 11.205

4 in total

16 in total

1. Selective dependence of H2-M3-restricted CD8 responses on IL-15.

Authors: Jürgen R Müller; Thomas A Waldmann; Sigrid Dubois
Journal: J Immunol Date: 2012-02-06 Impact factor: 5.422

2. IFNγ-Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment.

Authors: Christopher J Nirschl; Mayte Suárez-Fariñas; Benjamin Izar; Sanjay Prakadan; Ruth Dannenfelser; Itay Tirosh; Yong Liu; Qian Zhu; K Sanjana P Devi; Shaina L Carroll; David Chau; Melika Rezaee; Tae-Gyun Kim; Ruiqi Huang; Judilyn Fuentes-Duculan; George X Song-Zhao; Nicholas Gulati; Michelle A Lowes; Sandra L King; Francisco J Quintana; Young-Suk Lee; James G Krueger; Kavita Y Sarin; Charles H Yoon; Levi Garraway; Aviv Regev; Alex K Shalek; Olga Troyanskaya; Niroshana Anandasabapathy
Journal: Cell Date: 2017-06-29 Impact factor: 41.582

3. Pulmonary vaccination as a novel treatment for lung fibrosis.

Authors: Samuel L Collins; Yee Chan-Li; Robert W Hallowell; Jonathan D Powell; Maureen R Horton
Journal: PLoS One Date: 2012-02-17 Impact factor: 3.240

4. Augmented replicative capacity of the boosting antigen improves the protective efficacy of heterologous prime-boost vaccine regimens.

Authors: Pablo Penaloza-MacMaster; Jeffrey E Teigler; Rebecca C Obeng; Zi H Kang; Nicholas M Provine; Lily Parenteau; Stephen Blackmore; Joshua Ra; Erica N Borducchi; Dan H Barouch
Journal: J Virol Date: 2014-03-19 Impact factor: 5.103

5. Vaccinia vaccine-based immunotherapy arrests and reverses established pulmonary fibrosis.

Authors: Samuel L Collins; Yee Chan-Li; MinHee Oh; Christine L Vigeland; Nathachit Limjunyawong; Wayne Mitzner; Jonathan D Powell; Maureen R Horton
Journal: JCI Insight Date: 2016-04-07

6. The DC receptor DNGR-1 mediates cross-priming of CTLs during vaccinia virus infection in mice.

Authors: Salvador Iborra; Helena M Izquierdo; María Martínez-López; Noelia Blanco-Menéndez; Caetano Reis e Sousa; David Sancho
Journal: J Clin Invest Date: 2012-04-16 Impact factor: 14.808

7. Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice.

Authors: Joseph N Brewoo; Tim D Powell; Dan T Stinchcomb; Jorge E Osorio
Journal: Vaccine Date: 2010-07-12 Impact factor: 3.641

8. Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice.

Authors: Joseph N Brewoo; Tim D Powell; Jeremy C Jones; Nancy A Gundlach; Ginger R Young; Haiyan Chu; Subash C Das; Charalambos D Partidos; Dan T Stinchcomb; Jorge E Osorio
Journal: Vaccine Date: 2013-02-01 Impact factor: 3.641

9. Preexisting high frequencies of memory CD8+ T cells favor rapid memory differentiation and preservation of proliferative potential upon boosting.

Authors: Kathryn A Fraser; Jason M Schenkel; Stephen C Jameson; Vaiva Vezys; David Masopust
Journal: Immunity Date: 2013-07-25 Impact factor: 31.745

10. Buccal viral DNA as a trigger for brincidofovir therapy in the mousepox model of smallpox.

Authors: Ryan Crump; Maria Korom; R Mark Buller; Scott Parker
Journal: Antiviral Res Date: 2016-12-27 Impact factor: 10.103